Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 230

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Identification of prostate cancer biomarkers in urinary exosomes

Open access
Øverbye, Anders, Skotland, Tore, Koehler, Christian J., Thiede, Bernd, Seierstad, Therese, Berge, Viktor, Sandvig, Kirsten, Llorente, Alicia·2015·Oncotarget

Abstract

// Anders Øverbye 1,2 , Tore Skotland 1,2 , Christian J. Koehler 3,4 , Bernd Thiede 3,4 , Therese Seierstad 5 , Viktor Berge 6 , Kirsten Sandvig 1,2,4 and Alicia Llorente 1,2 1 Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital-The Norwegian Radium Hospital, Oslo, Norway 2 Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway 3 The Biotechnology Centre of Oslo, University of Oslo, Oslo, Norway 4 Department of Biosciences, University of Oslo, Oslo, Norway 5 Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway 6 Department of Urology, Oslo University Hospital, Oslo, Norway Correspondence to: Alicia Llorente, email: // Keywords : biomarkers, exosomes, extracellular vesicles, mass spectrometry, prostate cancer Received : April 30, 2015 Accepted : June 23, 2015 Published : July 13, 2015 Abstract Exosomes have recently appeared as a novel source of non-invasive cancer biomarkers since tumour-specific molecules can be found in exosomes isolated from biological fluids. We have here investigated the proteome of urinary exosomes by using mass spectrometry to identify proteins differentially expressed in prostate cancer patients compared to healthy male controls. In total, 15 control and 16 prostate cancer samples of urinary exosomes were analyzed. Importantly, 246 proteins were differentially expressed in the two groups. The majority of these proteins (221) were up-regulated in exosomes from prostate cancer patients. These proteins were analyzed according to specific criteria to create a focus list that contained 37 proteins. At 100% specificity, 17 of these proteins displayed individual sensitivities above 60%. Even though several of these proteins showed high sensitivity and specificity for prostate cancer as individual biomarkers, combining them in a multi-panel test has the potential for full differentiation of prostate cancer from non-disease controls. The highest sensitivity, 94%, was observed for transmembrane protein 256 (TM256; chromosome 17 open reading frame 61). LAMTOR proteins were also distinctly enriched with very high specificity for patient samples. TM256 and LAMTOR1 could be used to augment the sensitivity to 100%. Other prominent proteins were V-type proton ATPase 16 kDa proteolipid subunit (VATL), adipogenesis regulatory factor (ADIRF), and several Rab-class members and proteasomal proteins. In conclusion, this study clearly shows the potential of using urinary exosomes in the diagnosis and clinical management of prostate cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.4851

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 230

Metadata

Authors
Øverbye, A., Skotland, T., Koehler, C. J., Thiede, B., Seierstad, T., Berge, V., Sandvig, K., & Llorente, A.
Venue
Oncotarget
Published
2015-07-13
Volume
6
Issue
30
Pages
30357-30376
ISSN
1949-2553 (ISSN-L)
OpenAlex
W1910005513
Cited by
230
References
9
FWCI
7.98
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Identification of prostate cancer biomarkers in urinary exosomes. https://app.cochat.ai/papers/10.18632/oncotarget.4851
The paper
Øverbye, A., Skotland, T., Koehler, C. J., Thiede, B., Seierstad, T., Berge, V., Sandvig, K., & Llorente, A. (2015). Identification of prostate cancer biomarkers in urinary exosomes. Oncotarget. https://doi.org/10.18632/oncotarget.4851

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.